Diltiazem HCl Injection Rx
Generic Name and Formulations:
Diltiazem HCl 5mg/mL; soln for IV inj or infusion after dilution.
Various generic manufacturers
Indications for Diltiazem HCl Injection:
Temporary control of rapid ventricular rate in atrial fibrillation or flutter. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm.
Direct IV single injections (bolus): initially 0.25mg/kg over 2 minutes; if needed, may give second dose (0.35mg/kg) after 15 minutes; subsequent bolus doses should be individualized. If continuous IV infusion is needed, begin immediately after bolus administration. Initial infusion rate: 10mg/h; may increase in 5mg/h increments up to 15mg/h. May be maintained for up to 24 hours.
Sick sinus syndrome or 2nd- or 3rd-degree AV block (unless paced). Severe hypotension. Cardiogenic shock. Concomitant IV β-blockers. Atrial fibrillation or flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White syndrome or short PR syndrome. Ventricular tachycardia.
Have resuscitative equipment readily available. CHF. Renal or hepatic impairment. Hemodynamically compromised. Continuously monitor ECG and blood pressure. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Possible bradycardia, AV block, and/or depression of contractility with concomitant oral β-blockers. Additive effects with agents known to affect cardiac conduction. Avoid concomitant CYP3A4 inducers (eg, rifampin). Potentiated by cimetidine; may need to adjust diltiazem dose. May potentiate anesthetics, benzodiazepines, buspirone, carbamazepine, cyclosporine, quinidine; monitor.
Calcium channel blocker (CCB) (benzothiazepine).
Hypotension, inj site reactions (eg, itching, burning), vasodilation, arrhythmia; dermatological events (eg, erythema multiforme, exfoliative dermatitis; discontinue if occurs), hepatotoxicity, ventricular premature beats.
Formerly known under the brand name Cardizem.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|